Megestrol Acetate

Specifications

595-33-5CAS Number

209-864-5EC Number

[(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetateIUPAC Name

C24H32O4Chemical Formula

384.5 g/molMolecular Weight

MEGESTROL ACETATE; 595-33-5; Megestryl acetate; Megace; Niagestin; Megeron; Ovaban; Ovarid; Megace ES; Megestat; BDH 1298; Maygace; Pallace; Magestin; Volidan; SC 10363; NSC-71423; Megestil; Megesterol acetate; SC-10363; BDH-1298; 17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate; 17alpha-Acetoxy-6-dehydro-6-methylprogesterone; 6-Dehydro-6-methyl-17alpha-acetoxyprogesterone; 6-Methyl-6-dehydro-17alpha-acetoxyprogesterone; DTXSID9040683; SC10363; 17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione; TJ2M0FR8ES; 6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate; 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate; 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate; Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-; 6-Methyl-3,20-dioxopregna-4,6-dien-17-yl acetate; 17alpha-Acetoxy-6-methylpregna-4,6-diene-3,20-dione; 6-Methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione; CHEBI:6723; DTXCID7020683; NSC71423; 6-Methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone; 6-Methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate; Acetate, Megestrol; Megestol; Megostat; ApoMegestrol; LinMegestrol; NuMegestrol; Apo Megestrol; Lin Megestrol; Nu Megestrol; (9beta,10alpha)-17-(Acetyloxy)-6-methylpregna-4,6-diene-3,20-dione; RefChem:55565; MEGESTROL 17alpha-ACETATE; Ovaban Tablets 20 mg, Ovaban Tablets 5 mg; 6-Dehydro-6-methyl-17 alpha-acetoxyprogesterone; 17 Alpha-acetoxy-6-methylpregna-4,6-diene-3,20-dione; 6-Methyl-delta-4,6-pregnadien-17 alpha-ol-3,20-dione Acetate; 209-864-5; Megestrol-17-acetate; MFCD00056470; [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate; Megestrol 17.alpha.-acetate; MLS000028633; MLS001074091; SMR000058691; (8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate; Ovaban (Veterinary); Megestin; Megestrol acetate [USAN]; (8xi,9xi,10xi,13xi,14xi)-6-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate; CCRIS 372; Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-, acetate; EINECS 209-864-5; UNII-TJ2M0FR8ES; Megestrol acetole [Progestins]; Megestrol acetate [USAN:USP]; Megestrol acetole; Megestrol-Acetate; 17-alpha-Acetoxy-6-dehydro-6-methylprogesterone; 6-Dehydro-6-methyl-17-alpha-acetoxyprogesterone; 6-Methyl-6-dehydro-17-alpha-acetoxyprogesterone; NCGC00016516-01; CAS-595-33-5; Nia; Megace (TN); 17-(acetyloxy)-6-methylpregna-4,6-diene-3,20-dione; 6-Methyl-17-alpha-acetoxypregna-4,6-diene-3,20-dione; Megestrol acetate CRS; 6-Methyl-17-alpha-hydroxy-delta(sup 6)-progesterone acetate; 6-Methyl-6-dehydro-17.alpha.-acetylprogesterone; 6-Methyl-delta(sup 6)-dehydro-17-alpha-acetoxyprogesterone; 6-Methyl-delta4,6-pregnadien-17alpha-ol-3,20-dione acetate; Medroxyprogesterone Acetate EP Impurity G; 17.alpha.-Acetoxy-6-dehydro-6-methylprogesterone; 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone; 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone; Megestrol acetate (USP); Opera_ID_1511; Prestwick0_000956; Prestwick1_000956; Prestwick2_000956; Prestwick3_000956; 6-Methyl-delta(sup 4,6)-pregnadien-17-alpha-ol-3,20-dione acetate; SCHEMBL745; Megestrol acetate (Standard); BSPBio_000952; MLS000759501; MLS001424055; par-100,2; SPBio_003101; MEGESTROL ACETATE [MI]; BPBio1_001048; orb1224538; orb1309127; orb3025363; CHEMBL1201139; BDH1298; MEGESTROL ACETATE [VANDF]; MSK2207; MEGESTROL ACETATE [MART.]; HMS1570P14; HMS2051I20; HMS2090N04; HMS2097P14; HMS2235D16; HMS3714P14; MEGESTROL ACETATE [USP-RS]; MEGESTROL ACETATE [WHO-DD]; MEGESTROL ACETATE [WHO-IP]; Tox21_110469; Tox21_302360; EBC-17082; HY-13676R; LMST02030118; MSK2207-100A; AKOS015894927; MEGESTROL ACETATE [GREEN BOOK]; MSK2207-1000A; Tox21_110469_1; CCG-100899; CS-2065; DB00351; FM25040; MEGESTROL ACETATE [ORANGE BOOK]; NC00149; MEGESTROL ACETATE [EP MONOGRAPH]; 17-Acetoxy-6-methylpregna-4,20-dione; MEGESTROL ACETATE [USP MONOGRAPH]; NCGC00024196-03; NCGC00024196-05; NCGC00024196-07; NCGC00024196-17; NCGC00255456-01; (1R,3aS,3bR,9aR,9bS,11aS)-1-acetyl-5,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl acetate; AC-24570; AS-13384; HY-13676; SY076369; 17.alpha.-Acetoxy-6-methyl-4,20-dione; AB00490013; Megestrol acetate for system suitability CRS; NS00009122; Megestrol acetate for peak identification CRS; 17-Hydroxy-6-methylpregna-4,20-dione acetate; 17.alpha.-Acetoxy-6-methylpregna-4,20-dione; C08151; D00952; D91560; AB00383046-13; AB00383046-14; AB00383046-15; AB00383046_16; EN300-7480847; Pregna-4,20-dione, 17-(acetyloxy)-6-methyl-; Megestrol-17-acetate 100 |Ig/mL in Acetonitrile; SR-01000000258; Megestrol-17-acetate 100 microg/mL in Acetonitrile; Pregna-4,20-dione, 17-hydroxy-6-methyl-, acetate; Q6808975; SR-01000000258-4; 17-(Acetyloxy)-6-methypregna-4,6-diene-3,20-dione; BRD-K19507340-001-03-1; BRD-K19507340-001-22-1; MEDROXYPROGESTERONE ACETATE IMPURITY G [WHO-IP]; Megestrol acetate Solution in Acetonitrile, 1000ug/mL; Megestrol acetate Solution in Acetonitrile, 100ug/mL; Megestrol acetate, VETRANAL(TM), analytical standard; 17alpha-Acetoxy-6-methyl-4,6-pregnadiene-3,20-dione; Megestrol acetate, analytical standard, for drug analysis; MEDROXYPROGESTERONE ACETATE IMPURITY G [EP IMPURITY]; WLN: L E5 B666 OV KU MUTJ A1 E1 FV1 FOV1 L1; 6-Methyl-17.alpha.-hydroxy-.delta.(sup 6)-progesterone acetate; Megestrol Acetate Working Standard (Secondary Reference Standard); Megestrol acetate, European Pharmacopoeia (EP) Reference Standard; 6-METHYL-3,20-DIOXOPREGNA-4,6-DIEN-17-YL ACETATE [WHO-IP]; Megestrol acetate, United States Pharmacopeia (USP) Reference Standard; Megesgtrol Acetate, Pharmaceutical Secondary Standard; Certified Reference Material; Megestrol acetate for peak identification, European Pharmacopoeia (EP) Reference Standard; Megestrol acetate for system suitability, European Pharmacopoeia (EP) Reference Standard; (8R,9S,10R,13S,14S,17R)-17-Acetyl-6,10,13-trimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylacetat; Megace; Ovaban; (8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate; Megestrol acetate; [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate;Synonyms